GlassScriptPhysician profile
Sahil Bakshi
NPI 1659368199
$167,177.75
in general payments reported to CMS, 2019-2025
43 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $17K · 2021: $12K · 2022: $19K · 2023: $25K · 2024: $29K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Food and Beverage: $7,624 · Travel and Lodging: $2,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,426.00 |
| Food and Beverage | $7,624.17 |
| Travel and Lodging | $2,875.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $108,914.62 | 2019-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $28,075.00 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22,351.66 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,925.82 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $902.76 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Novo Nordisk INC | $733.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $451.55 | 2019-2023 | Lexiscan |
| Amgen INC. | $399.46 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $381.90 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $244.83 | 2022-2025 | Camzyos, Eliquis |
| Janssen Research & Development, LLC | $222.00 | 2021 | |
| Heartflow, INC. | $220.80 | 2019-2023 | Ffrct |
| Amarin Pharma, INC. | $190.50 | 2021-2022 | |
| Inari Medical, INC. | $186.46 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kiniksa Pharmaceuticals International, Plc | $164.13 | 2024 | Arcalyst |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $158.06 | 2020-2023 | Farxiga |
| Pfizer INC. | $153.44 | 2021-2024 | |
| Esperion Therapeutics, INC. | $142.34 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.51 | 2019-2024 | Lifevest |
| Getinge USA Sales, LLC | $121.14 | 2022 | |
| Alnylam Pharmaceuticals INC. | $113.42 | 2022-2025 | Onpattro, Amvuttra |
| Inspire Medical Systems, INC. | $99.77 | 2023-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $92.59 | 2019-2024 | |
| Boston Scientific Corporation | $87.70 | 2019-2023 | Watchman Access System, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.94 | 2020-2025 | Jardiance |
| Medtronic Vascular, INC. | $71.44 | 2020 | |
| Siemens Medical Solutions USA, INC. | $63.60 | 2022-2025 | Somatom Pro.Pulse |
| Impulse Dynamics (USA) INC. | $61.61 | 2023 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $55.38 | 2019-2025 | Evkeeza |
| Abiomed | $54.32 | 2025 | |
| Philips North America LLC | $49.41 | 2025 | Extended Holter |
| Bridgebio Pharma, INC. | $44.05 | 2025 | Attruby |
| Sandoz INC. | $42.35 | 2023 | Treprostinil |
| Baxter Healthcare | $38.10 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Acarix USA INC. | $27.59 | 2024 | Cadscor System |
| Abbott Laboratories | $24.61 | 2022 | |
| Itamar Medical INC | $21.16 | 2025 | Watchpatone |
| Cook Medical LLC | $19.38 | 2023 | Zilver Ptx |
| Kiniksa Pharmaceuticals, LTD. | $16.58 | 2023 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $12.73 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.65 | 2021 | |
| Althera Pharmaceuticals LLC | $10.25 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahil Bakshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.